SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending due to its selection by the U.S. Department of Commerce to distribute economic data on-chain, a move seen as a major step for decentralized infrastructure. The community is actively discussing potential price targets and the broader implications of government adoption of blockchain technology. Some users also believe that this could be the start of a long term hold.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a memecoin on the Bitcoin network, is trending as the community rallies around its fair distribution and potential to outperform other meme coins. Some believe it could become the leading meme on Bitcoin, citing its strong community and organic growth. The potential for listings on major exchanges and the backing of a publicly listed company, $CBLO, are also fueling interest.

WorldFinancial

World Financial (WLFI.X) is trending as traders discuss its potential value relative to its reserves and speculate on future price movements. The community is focused on the possibility of FOMO driving the price up, with some pointing to upcoming conferences and strategic directions as catalysts. Ongoing conversations also involve its association with political figures and the potential impact of regulatory developments.

Wrapped Centrifuge

Wrapped Centrifuge is gaining attention as community members actively discuss its potential breakout and encourage others to take a look. Some users point to news and increasing volume as potential catalysts, while others highlight its low supply. There's also discussion around the difference between $CFG.X and $WCFG.X.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a major land sale, which the company projects will significantly boost its net asset value. The community is discussing the stock's low float and potential for a substantial breakout, drawing comparisons to other recent low-float runners. Some traders are closely watching key breakout levels, anticipating a rapid move upwards if these levels are breached.

StickyFam

StickyFam ($FAM.X) is trending as the community rallies around its potential, highlighting its growing follower base and recent listing on BingX. Comparisons to coins within the $DOGE.X and $SOL.X ecosystem are circulating, with many believing that $FAM.X is still early and poised for significant growth due to upcoming catalysts like CEX listings.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the community discusses its potential as the 'DOGE of Bitcoin' and its fair, presale-free distribution. Bullish sentiment surrounds CBLO's increasing treasury holdings of DOG coins, with some anticipating ETF possibilities and tier 1 exchange listings. Conversation highlights $DOG's strong community and its activities within the Bitcoin ecosystem, particularly regarding Runestones and Ordinals.

Dynamix Corp. is a blank check company, which engages for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 13, 2024 and is headquartered in Houston, TX.

Dynamix Corp - Ordinary Shares - Class A

The ticker change from DYNX to ETHM is driving interest, as the company moves closer to its merger with The Ether Machine. Community members are actively discussing the company's Ethereum holdings relative to its market cap and comparing it to other ETH-related stocks. Some are also speculating on the potential impact of new ETH acquisitions on the share price.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa ($AA) is trending as the community discusses its strong earnings report and potential benefits from tariffs, though some caution about potential headwinds. Bullish sentiment is fueled by analyst upgrades and a positive long-term outlook, while others are wary of short-term volatility. Community members are actively trading options, anticipating price movements based on the latest news.

PancakeSwap is an automated market maker (“AMM”) that allows two tokens to be exchanged on the Binance Smart Chain. It is fast, cheap, and allows anyone to participate.

PancakeSwap

PancakeSwap is trending as the community discusses the implications of its ongoing CAKE token burns and supply management, with some hopeful for a price increase. Recent integrations and features, like social logins and stock perps, are also sparking interest. Traders are weighing the potential impact of these developments on CAKE's value amid broader market movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Kura Oncology Stock?

KURA Stock Rises More Than 15% This Past Week: Here's Why

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's valuation stands at just $4 million.<ul><li>Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness. A sensitizer is a drug designed to enhance the effectiveness of radiation by making cancer cells more susceptible to damage while sparing healthy cells. This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation. &nbsp;</li><li>Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. While several peer companies in Phase 2 trials boast market caps exceeding $500 million, Shuttle’s valuation stands at just $4 million. This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. &nbsp;</li><li>Founded by Georgetown University faculty, Shuttle Pharma is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.</li></ul>&nbsp;Shuttle Pharmaceuticals: Revolutionizing Radiation Therapy by Making it More Effective at Killing Cancer Cells while Sparing Healthy Cells<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals/">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is a clinical-stage biotech company specializing in therapies that enhance the efficacy of radiation therapy while minimizing side effects. Beyond Ropidoxuridine, Shuttle Pharma’s pipeline includes promising candidates like SP-2-225 and SP-1-303, along with diagnostic tools that could streamline FDA approval and open additional revenue streams.Dr. Anatoly Dritschilo, the company’s CEO, brings decades of experience as a radiation oncology leader and professor at Georgetown University. His tenure at the institution has cemented his reputation as an innovator in radiosensitization and therapeutic resistance strategies.&nbsp;Hope for Those Facing a Ruthless CancerGlioblastoma (GBM) is one of the deadliest cancers, with a five-year survival rate of just 6.9% and an average survival of eight months. It impacts cognition, mood, and independence, placing emotional and financial burdens on patients and families. With only a handful of FDA-approved treatments, GBM remains a significant challenge, but innovations like Shuttle Pharma’s Ropidoxuridine offer hope for better outcomes.&nbsp;Pipeline Overview and Flagship DrugShuttle Pharma’s pipeline includes:<ul><li>Ropidoxuridine (IPdR): Their flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes. The drug has received an Orphan Drug Designation, ensuring market exclusivity upon approval (3). Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.</li><li>SP-2-225: A preclinical HDAC6 inhibitor targeting immune activation post-RT. HDAC6 inhibitors are emerging as a transformative class of drugs with the potential to improve tumor recognition by the immune system (4). This drug could have broad applications combined with radiation therapy and other immune therapies, addressing a large oncology market.</li><li>SP-1-303: Another preclinical asset targeting estrogen receptor-positive breast cancers, a subtype that represents a significant portion of all breast cancer diagnoses. Its unique mechanism of action and potential synergy with current hormonal treatments create substantial commercial potential.</li></ul><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shuttle_pharma_pipeline_8164d4c4cb.png" alt="shuttle-pharma-pipeline.png">&nbsp;Market Potential for Ropidoxuridine and Other CandidatesRadiation sensitizers represent a multi-billion-dollar opportunity. The global radiation therapy market is projected to grow significantly, reaching $14.18 billion by 2028 (2). Approximately 50% of all cancer patients undergo radiation therapy, amounting to a substantial number of patients annually in the US alone (1). A significant portion of these patients are treated with curative intent, offering a target market potentially worth billions for sensitizing agents.With glioblastoma as the initial target, Shuttle’s technology could eventually expand into other cancer types where radiation is a core treatment modality, such as lung, breast, and gastrointestinal cancers. By reducing radiation toxicity and improving tumor control, Ropidoxuridine could become an essential adjunct to standard cancer care.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/global_radiation_therapy_market_graph_9d83a88dbe.jpeg" alt="global-radiation-therapy-market-graph.jpeg">Simple Mechanism of Action and Proven SafetyRopidoxuridine acts as a prodrug, metabolized into IUdR upon ingestion. IUdR incorporates into cancer DNA, enhancing RT-induced DNA damage while sparing healthy cells.In layman’s terms, Ropidoxuridine is like a “homing beacon” for radiation therapy, guiding the radiation to attack cancer cells while avoiding healthy tissues. This straightforward and targeted approach significantly increases the likelihood of clinical success compared to more complex therapies.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/how_does_ropidoxuridine_work_17eaa74e99.png" alt="how-does-ropidoxuridine-work.png">Comparative Analysis: Valuation vs. PeersBiotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million (5). Currently valued at approximately $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the upside potential.&nbsp;Similar Stage Comparisons: Phase 2 Enrollment<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/leap-therapeutics">Leap Therapeutics (NASDAQ: LPTX)</a><ul><li>Market Cap: Approximately $82 million</li><li>Focus: Antibody-based therapies targeting immune modulation in cancer.</li><li>Pipeline: DKN-01, currently in Phase 2 for gastric and gynecologic cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">(4)</a>.</li><li>Comparison Insight: Leap Therapeutics commands a valuation over 20x that of Shuttle Pharma, underscoring the latter’s deep undervaluation relative to its stage of development.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/nextcure">NextCure (NASDAQ: NXTC)</a><ul><li>Market Cap: Approximately $23 million</li><li>Focus: Immune therapies targeting novel tumor-specific antigens.</li><li>Pipeline: NC318, currently in Phase 2 trials for advanced solid tumors.</li><li>Comparison Insight: NextCure reflects the market’s optimism for immune-oncology therapies in Phase 2 trials.</li><li>Demonstrated Efficacy Comparisons: Post-Positive Phase 2</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/kura-oncology">Kura Oncology (NASDAQ: KURA)</a><ul><li>Market Cap: Approximately $620 million</li><li>Focus: Precision oncology for genetically defined cancers.</li><li>Pipeline: Tipifarnib, demonstrating efficacy in Phase 2 for HRAS-mutant cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">(6)</a>.</li><li>Comparison Insight: Kura highlights the potential valuation growth when efficacy is shown in Phase 2 for a targeted therapeutic.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/adicet-bio">Adicet Bio (NASDAQ: ACET)</a><ul><li>Market Cap: Approximately $76 million</li><li>Focus: Allogeneic gamma-delta T cell therapies for oncology.</li><li>Pipeline: ADI-001, demonstrating Phase 2 efficacy in B-cell lymphomas.</li><li>Comparison Insight: Adicet underscores how valuation grows post-efficacy, aligning with Shuttle Pharma’s potential trajectory.</li></ul>&nbsp;An Accomplished Team Backed by Prestigious InstitutionsShuttle Pharma’s leadership is grounded in expertise, with key team members boasting extensive experience in oncology drug development:<ul><li>Dr. Anatoly Dritschilo: CEO and co-founder, a globally recognized radiation oncology expert with over 40 years of experience. Dr. Dritschilo has published extensively on radiation therapy and drug discovery and is an innovator in developing strategies for radiosensitization and therapeutic resistance.</li><li>Dr. Tyvin Rich: Medical Director with experience at MD Anderson and Harvard, specializing in radiation sensitizers.</li><li>Dr. Mira Jung: Scientific Director and co-founder, a professor of Radiation Medicine at Georgetown University.</li></ul>The rest of the team comprises an impressive roster of PhDs, MDs, and industry veterans with decades of combined experience developing oncology therapies and navigating FDA regulatory pathways.Strong Insider Ownership and Shareholder AlignmentWith 28.3% insider ownership, including a significant investment from the CEO, Shuttle Pharma’s management is deeply aligned with shareholder interests. This rare level of insider ownership reflects confidence in the company’s potential. High insider ownership ensures that decision-makers have “skin in the game,” aligning their financial interests with investors and creating trust in long-term value creation. Additionally, if clinical data supports efficacy, the small public float (2.9 million shares) positions the stock for dramatic price appreciation.Conclusion: The Undervalued Biotech to WatchShuttle Pharma’s small float, strong leadership, and groundbreaking focus on radiation sensitizers position it as one of the most undervalued opportunities in biotech. With a Phase 2 trial underway and a massive addressable market, Shuttle could redefine cancer treatment while offering exponential upside for investors. Comparisons to higher-valued peers only underscore the gap—and the potential for rapid revaluation if results prove successful.Shuttle Pharma’s other drug candidates, including SP-2-225 and SP-1-303, offer compelling bonuses for investors. These unique yet complementary assets could potentially expand Shuttle’s market reach in oncology. Additionally, the company’s diagnostic tools present a unique opportunity: they often have more streamlined FDA approval processes than therapeutics and could potentially be spun off as a standalone business, unlocking significant shareholder value.References<ol><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/basics.html">American Cancer Society: Radiation Therapy Overview</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.researchandmarkets.com/report/radiation-therapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kpswcb&amp;utm_campaign=1977747+-+Global+Radiation+Therapy+Market+with+Focus+on+LINAC%2c+2024+Market+Report%3a+A+%2414.18+Billion+Market+in+2028%2c+Registering+a+Projected+CAGR+of+6.75%25+During+2024-2028&amp;utm_exec=carimspi">Global Radiation Therapy Market Report</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=519016">FDA Orphan Drug Designation List</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">Leap Therapeutics Corporate Pipeline</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/">Biotech Valuation Trends</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">Kura Oncology: Pipeline</a></li></ol>This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

Equity

Shares of Kura Oncology Inc. ($KURA), a clinical-stage biopharma company focused on cancer therapies, fell 37%&nbsp;by Thursday noon following a collaboration with Japan’s Kyowa Kirin, but retail sentiment remained strong.Kura said it has entered into a global strategic collaboration with Kyowa Kirin to develop and commercialize its blood cancer-focused therapy Ziftomenib. The therapy is an “oral menin inhibitor being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies,” according to a company statement. Acute myeloid leukemia&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/markets/deals/kura-oncology-partner-with-kyowa-kirin-blood-cancer-therapy-2024-11-20/">affects</a>&nbsp;about 20,000 people in the US every year.Under the terms of the agreement, Kura will receive an upfront payment of $330 million and expects to receive up to $420 million in near-term milestone payments, said the statement.In addition, Kura is eligible to receive additional development, regulatory and commercial milestone payments of $741 million, totaling up to $1.161 billion in payments for milestones and the opt-in for solid tumor indications.Retail sentiment on the stock rose to ‘extremely bullish’ (92/100) from ‘neutral’ (52/100) a week ago. Message volumes rose to ‘extremely high’ levels (85/100) from ‘normal’ (53/100).<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_21_at_10_13_22_PM_4c61dcb216.png" alt="Screenshot 2024-11-21 at 10.13.22 PM.png" width="1304" height="290"><figcaption>KURA sentiment and message volumes on Nov 21 as of 11:43 am ET| Source: Stocktwits</figcaption></figure>“The deal provides a certain level of valuation," Mizuho Securities analyst Salim Syed was quoted as&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investors.com/news/technology/kura-oncology-kyowa-kirin-deal-leukemia-kura-stock/">saying</a>&nbsp;by Investor’s Business Daily. "However, on the other hand, a collaboration here likely detracts from the near-term potential takeout narrative, which certainly has been something some investors had been articulating."KURA stock is up 35.35% year-to-date.For updates and corrections, email newsroom@stocktwits.com

Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish

Retail sentiment on the stock rose to ‘extremely bullish’ (92/100) from ‘neutral’ (52/100) a week ago. Message volumes rose to ‘extremely high’ levels. 

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26...

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration...

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA Research Report) and Aquestive Therapeutics...

Kura Oncology reports inducement grants under Nasdaq listing rule

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the Company ) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURA Kura Oncology Inc